The 'risk' here is often carried by publicly funded research. ~6.2 billion for glp
The private 'investment' comes in manufacturing, scale and marketing.
Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.